在肿瘤树突状细胞(DC)疫苗研究领域，怎样提高抗原肽DC疫苗在体内抗癌生物活性是拟待解决的难题。基于我们前期工作研制出的新载体M/CpG-ODN修饰纳米脂质体，本项目拟研制M/CpG-ODN修饰纳米脂质体装载肿瘤抗原肽制备成一种"M介导/CpG-ODN激活肿瘤特异性DC生物反应调节剂"，然后将其接种荷瘤鼠靶向活化DC形成体内"M介导/CpG-ODN激活肿瘤特异性DC生物反应器"，探索其体内抗肿瘤作用及机制。该生物反应器不仅可以避免抗原稀释和降解，而且可以实现抗原体内靶向DC，另外,其CpG-ODN可以作为佐剂活化DC，改善肿瘤免疫抑制环境,这必将大大提高肿瘤抗原肽DC疫苗在体内抗肿瘤的有效性。通过上述研究，不仅为研制理想的肿瘤抗原肽载体提供新的思路，而且为肿瘤抗原肽DC疫苗提供新的方法学和理论指导，这将为载体系统和肿瘤生物治疗研究领域带来新的突破，因而具有重要的理论意义和广泛应用前景。

In the research field of tumor dendritic cell vaccine , it is necessary to improve anticancer activity of the tumor antigen peptide DC vaccine in vivo. Based on our previous work developed a novel carrier M/CpG-ODN modified nano-liposomes, the project intends to use the M/CpG-ODN modified nano liposome-encapsulated tumor antigen peptide to prepare a "M-mediated/CpG-ODN activated tumor-specific DC biological response modifier", then inoculate it into tumor-bearing mice to form the M-mediated/CpG-ODN activated tumor-specific DC bioreactor" by targeting and activating DC in vivo, as well as to explore anti-tumor effect and mechanism of the bioreactor. The bioreactor not only can avoid degradation and dilution of antigen but also can target DC in vivo. Meanwhile, the CpG-ODN of the bioreactor can be used as an adjuvant to activate DC and improve tumor immunosuppressive environment. These features could greatly enhance the anti-tumor effectiveness of the antigen peptide DC vaccine in vivo. This research not only provide new ideas for the development of an ideal tumor antigen peptide carrier but also provide new methodological and theoretical guidance for the tumor antigen peptide DC vaccine, which bring new breakthroughs for the research areas of the carrier system and tumor biotherapy. Therefore this research has important theoretical significance and wide application prospects.